Adcendo

#Adcendo #Antibody drug conjugate (ADC) #Financing #Fundraising

Adcendo raises $135 million to advance ADC pipeline

Biotech company Adcendo has announced the successful closing of an oversubscribed $135 million Series B financing round.   Proceeds from the fundraise will be used to accelerate the development of the company’s ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programmes. … Read More

#Business & Investment #News

Antibody drug conjugate
#Adcendo #Antibody drug conjugate (ADC) #Cancer research #Multitude Therapeutics

Agreement facilitates differentiated ADC targeting Tissue Factor 

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.  TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer,… Read More

#Cancer Research #News